Hosted on MSN
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052
Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results